论文部分内容阅读
目的:探讨BIPAP呼吸机联合纳洛酮治疗慢性阻塞性肺疾病(COPD)并Ⅱ型呼吸衰竭的临床疗效。方法:将98例慢性阻塞性肺疾病(COPD)并Ⅱ型呼吸衰竭的患者,随机分为观察组与对照组各49例,所有患者都给予抗感染、解痉平喘、止咳化痰、支持等临床常规治疗,对照组单独应用BIPAP呼吸机进行治疗,观察组在常规治疗基础上进行BIPAP呼吸机联合纳洛酮治疗,观察两组患者治疗前后生命体征及血气情况。结果:治疗后2h两组患者的pH值、PaO2、PaCO2比较差异无统计学意义(P>0.05),治疗后12h、24h的pH值、PaO2、PaCO2两组均明显改善(P<0.05),观察组较对照组更优,差异有统计学意义(P<0.05)。结论:BIPAP呼吸机联合纳洛酮治疗COPD并II型呼吸衰竭比单独应用BIPAP呼吸机治疗效果更优。
Objective: To investigate the clinical efficacy of BIPAP combined with naloxone in the treatment of chronic obstructive pulmonary disease (COPD) and type Ⅱ respiratory failure. Methods: A total of 98 patients with chronic obstructive pulmonary disease (COPD) and type Ⅱ respiratory failure were randomly divided into observation group and control group, with 49 cases in each group. All patients were given anti-infective, antispasmodic and anti-asthma, cough and phlegm, The patients in the control group were treated with BIPAP ventilator alone. The observation group was treated with BIPAP combined with naloxone on the basis of routine treatment. The vital signs and blood gas of the two groups were observed before and after treatment. Results: There was no significant difference in pH value, PaO2 and PaCO2 between the two groups at 2h after treatment (P> 0.05). The pH, PaO2 and PaCO2 at 12h and 24h after treatment were significantly improved (P <0.05) The observation group was better than the control group, the difference was statistically significant (P <0.05). Conclusion: BIPAP combined with naloxone in treating COPD and type II respiratory failure is better than BIPAP alone.